Second, our TS-based Bradley–Terry model revealed that mutations in splicing genes, in TP53, and in CHIP-associated genes (DNMT3A and TET2) were likely initiating events in the development of AML with abn(7). This evidence concerns the gene TET2 and acute myeloid leukemia.